Eton Pharmaceuticals has launched IMPAVIDO (miltefosine) capsules and now holds exclusive U.S. commercialization rights for the antileishmanial drug. The company has integrated Eton Cares patient support, including a $0 co-pay for eligible commercially insured patients and expanded patient assistance programs. Distribution is centralized through Anovo Specialty Pharmacy for outpatient prescriptions, inpatient consignment and urgent access coordination. IMPAVIDO is indicated for adults and adolescents at least 12 years old weighing at least 30 kilograms for specified forms of leishmaniasis. The launch includes safety requirements covering pregnancy, reproductive potential, renal and hepatic monitoring, gastrointestinal effects, platelet counts and severe skin reactions.